• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Improved islet encapsulation device for the treatment of type 1 diabetes [PreClinical]

byCorinne FoleyandRadhika Agarwal
February 5, 2018
in Chronic Disease, Endocrinology, Preclinical
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. A device for islet transplantation for type 1 diabetes was designed and demonstrated to be safe and retrievable in animal models.

2. When tested in mice and dogs, this device successfully reduced glucose levels.

Evidence Rating Level: 2 (Good)

Study Rundown: Type 1 diabetes is an autoimmune condition that attacks pancreatic islets, preventing successful insulin secretion and glucose control. Currently, this condition is managed through daily insulin injections. However, islet transplantation would provide a better and longer-lasting treatment of this condition. The development of a functional islet cell encapsulation device that does not require immunosuppressants or damage cells has, as of yet, proven challenging. Recently, researchers at Cornell University made significant progress in the development of such a device.

These researchers call their device TRAFFIC, or thread-reinforced alginate fiber for islet encapsulation. Rat islets are encapsulated in an alginate hydrogel, which is necessary to prevent immune rejection by the host. The hydrogel containing the rat islets surrounds a polymer thread to form a cylindrical device. When this device was transplanted into normal and diabetic mice, the blood glucose levels of diabetic mice was reduced, and the mice remained normoglycemic for 4 weeks. Additionally, no significant tissue damage, fibrosis, or cellular overgrowth was noted on the device or peritoneum of these mice. Subsequently, human islets were transplanted into immunodeficient diabetic mice with similar results to the rat islet studies. Finally, TRAFFIC was implanted into two dogs. Following implantation, the islets were found to be functional and resulted in no significant damage or inflammation.

This study is one of the first to outline the development of an effective and retrievable therapy involving islet transplantation for type 1 diabetes. However, the in vivo efficacy of this device in humans, the number of islets needed for successful treatment, and the length of time this device needs to stay implanted for long term success in humans are all variables that need to be assessed. Despite the unknowns, these initial analyses provide great promise for an improved treatment for type 1 diabetes.

Click to read the study in PNAS

RELATED REPORTS

The ACCORD trial: Intensive glucose control associated with increased mortality [Classics Series]

Increases in muscle-strengthening activities may reduce mortality risk and certain diseases

Associations of dietary patterns and lifestyle modifications with glycemic control in diabetic patients

Relevant Reading: Beta-cell replacement strategies for diabetes

In-Depth [animal study]: To create a nanoporous and durable thread, a coated nylon suture was twisted into a 4-strand thread and cross-linked with CaCl2. An alginate hydrogel solution was molded and formed around the thread. TRAFFIC was then implanted into the peritoneal cavity of immunocompetent mice and the device was analyzed 2 weeks and 7 months following implantation. Little cellular overgrowth or fibrosis were found using microscopy, photography, and H&E staining demonstrating biocompatibility of the device. Cell viability of the encompassed islets was next assessed through exposure of the islets to solutions with varying glucose concentrations and assessing the concentration changes of glucose and insulin over time. It was confirmed that the islets were responding to the change in glucose levels through increasing insulin secretion.

The ability of this device to correct diabetes in mice was then tested by transplanting the TRAFFIC device, containing around 475 rat islets, into mice induced with diabetes through the administration of 50 mg/kg streptozocin (STZ). The blood glucose levels of diabetic mice reduced to normal range within 2 days and were maintained for 4 weeks following removal (p< 0.05). Similar results demonstrating effective glucose control and insulin secretion were obtained when TRAFFIC, containing human islets, was implanted into STZ-induced diabetic, immunodeficient, SCID-beige mice.

Finally, TRAFFIC functionality and safety was ultimately tested in two dogs. TRAFFIC was laparoscopically implanted near the liver of these dogs and led to little fibrosis on the device and tissue containing the implant. The islets in the implant were found to be functional following implantation resulting in no significant increase in adverse immune reactions as assessed through blood work involving white blood cell counts and quantification of liver enzymes.

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: diabetes
Previous Post

Recurrent Salmonella enterica Typhimurium infection disables host protection against intestinal inflammation [PreClinical]

Next Post

Transgender, gender nonconforming youths underutilize health care

RelatedReports

Classics Series, Landmark Trials in Medicine
Emergency Classics

The ACCORD trial: Intensive glucose control associated with increased mortality [Classics Series]

May 4, 2022
Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors
Cardiology

Increases in muscle-strengthening activities may reduce mortality risk and certain diseases

May 3, 2022
Chronic Disease

Associations of dietary patterns and lifestyle modifications with glycemic control in diabetic patients

April 29, 2022
Filtered-sunlight may effectively treat neonatal jaundice in resource-poor settings
Cardiology

Light exposure during sleep may alter glucose metabolism and impair cardiometabolic function

April 19, 2022
Next Post
AAP reaffirms support for adolescents’ rights to confidential reproductive care

Transgender, gender nonconforming youths underutilize health care

AAP policy statement discusses recommended immunizations

AAP policy statement discusses recommended immunizations

Radiofrequency catheter ablation effective as first-line therapy for atrial fibrillation [RAAFT-2 trial]

2 Minute Medicine Rewind February 5, 2018

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
  • #VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.